Subtyping Primary Aldosteronism with Para-chloro-2-[18F]fluoroethyl-etomidate ([18F]CETO)
2023-508254-26-00
Phase 2 other active
Quick answer
Subtyping Primary Aldosteronism with Para-chloro-2-[18F]fluoroethyl-etomidate ([18F]CETO) for Primary aldosteronism is a Phase 2 program (other) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- Primary aldosteronism
- Phase
- Phase 2
- Modality
- other
- Status
- active